In this presentation we will overview the best patient engagement strategies across the medicines development continuum and focus on our actions to improve patient recruitment and retention.
Active involvement of patient representatives early in the design phase of development programmes has become vital for the successful conduct of clinical trials. Patient panels discuss what patients expect from clinical trials, and what they need to gain a positive experience of participating in a trial. Patient boards help define patient-relevant outcomes by specifying what constitutes real benefit and value for patients. This session will reflect on the lessons learned to date from involving patient representatives in clinical trial design and explore the path forward.
Active involvement of patient representatives early in the design phase of development programmes has become vital for the successful conduct of clinical trials. Patient panels discuss what patients expect from clinical trials, and what they need to gain a positive experience of participating in a trial. Patient boards help define patient-relevant outcomes by specifying what constitutes real benefit and value for patients. This session will reflect on the lessons learned to date from involving patient representatives in clinical trial design and explore the path forward.
• Comparing the perspectives of industry, research and patients
• What are best practices in involving patient representatives in clinical trial design?
• What are key challenges, and how are they overcome?
• Discussing the way to go to take patient involvement to the next level
Bringing the voice of patients and sites into end-to-end clinical development will provide a good trial experience for trial participants, bring innovative treatments to patients faster by accelerating clinical development and ensure that new treatments fulfil patients’ needs and expectations.
• Examples for understanding the voice of patients and sites and bringing it into clinical development
• The importance of bringing all stakeholders together, including partnerships with patient organisations and healthcare professionals
• Challenges and future opportunities
In this presentation we will overview the best patient engagement strategies across the medicines development continuum and focus on our actions to improve patient recruitment and retention.
• Overview of best PE strategies across the medicines development continuum
• What we can do to improve patient recruitment and retention and some lessons learned over the COVID-19 pandemic
• Initiatives we have already implemented at Ipsen and in collaboration with our partners
• Further considerations
COVID-19 accelerated Teva to focus on the need to vision and implement a DCT strategic approach in our late phase studies, understanding that this may be the future for running clinical studies regardless “crisis” situations. The presentation is addressing what Teva gained since the COVID-19 pandemic appeared, what was our vision’s focus, our implementation strategy and efforts for leading a paradigm shift to the way we have conducted clinical trials so far.
• Background
• Building a streamline
• Identifying the stakeholders
• Continuous mitigation
• Implementation
Pharma trials are not all that accessible and attractive to patients. We are often confronted with this when recruitment is slow and investigators are desperate. What would make a protocol more attractive to a patient? And what putts them off? And how can we make it more attractive and easier to stay in the study for the whole treatment duration? The global pandemic has forced some changes in the conduct of clinical research. May be this was just that little push we needed. Let us jointly look at point for improvement for future trials.
• Pitt falls of clinical trial protocols
• Opportunities for clinical trial protocols
• The pandemic as a catalytic converter for more patient centred clinical trials Maarten
Bringing the voice of patients and sites into end-to-end clinical development will provide a good trial experience for trial participants, bring innovative treatments to patients faster by accelerating clinical development and ensure that new treatments fulfil patients’ needs and expectations.
Pharma trials are not all that accessible and attractive to patients. We are often confronted with this when recruitment is slow and investigators are desperate. What would make a protocol more attractive to a patient? And what putts them off? And how can we make it more attractive and easier to stay in the study for the whole treatment duration? The global pandemic has forced some changes in the conduct of clinical research. May be this was just that little push we needed. Let us jointly look at point for improvement for future trials.
COVID-19 accelerated Teva to focus on the need to vision and implement a DCT strategic approach in our late phase studies, understanding that this may be the future for running clinical studies regardless “crisis” situations. The presentation is addressing what Teva gained since the COVID-19 pandemic appeared, what was our vision’s focus, our implementation strategy and efforts for leading a paradigm shift to the way we have conducted clinical trials so far.
”Excellent conference. Great discussions. The size of this conference allows for great dialogues.
Global Patient Centricity Director, Ipsen
Inside you will find
